Ellen Zagrebelsky
Geriatric Medicine · Philadelphia, PANPI 1275584807
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,134 and has fallen 88.0% since, to $375 in 2025. Among geriatric medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $86.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$998
- AbbVie$989
- Johnson & Johnson$983
- Novo Nordisk$572
- E.r. Squibb & Sons, L.L.C.$488
- Lilly USA, LLC$425
- plus $3K from 18 others
What the payments were for
- Food & beverage$7,186100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $998 |
| AbbVie(2 entities) | 10 | $989 |
| Johnson & Johnson(2 entities) | 11 | $983 |
| Novo Nordisk | 6 | $572 |
| E.r. Squibb & Sons, L.L.C. | 10 | $488 |
| Lilly USA, LLC | 8 | $425 |
| Sanofi-aventis U.S. LLC | 2 | $267 |
| Aimmune Therapeutics, Inc. | 2 | $250 |
| Amgen | 2 | $250 |
| Amarin Pharma, Inc. | 2 | $249 |
| GSK | 4 | $226 |
| Daiichi Sankyo Inc. | 2 | $199 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $174 |
| Medtronic | 1 | $161 |
| Boston Scientific | 1 | $129 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Nestle Healthcare Nutrition Inc. | 1 | $125 |
| Ironwood Pharmaceuticals, Inc | 1 | $125 |
| Intuity Medical Inc | 1 | $117 |
| Esperion Therapeutics, Inc. | 1 | $114 |
| Avanir Pharmaceuticals, Inc. | 1 | $103 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $82 |
| Merck | 2 | $25 |
| Novartis | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,186 in reported general payments places this provider in the 90th percentile of 217 geriatric medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 116 | $107,264 |
| LinzessLinaclotide | 153 | $83,731 |
| VascepaIcosapent Ethyl | 171 | $61,383 |
| EliquisApixaban | 91 | $59,002 |
| JanuviaSitagliptin Phosphate | 74 | $38,678 |
| TradjentaLinagliptin | 71 | $35,985 |
| TrulicityDulaglutide | 24 | $22,284 |
| FarxigaDapagliflozin Propanediol | 37 | $20,857 |
| NamzaricMemantine Hcl/Donepezil Hcl | 34 | $19,813 |
| RybelsusSemaglutide | 13 | $12,663 |
| XareltoRivaroxaban | 19 | $12,201 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $10,330 |
| Dexlansoprazole DrDexlansoprazole | 50 | $10,050 |
| MyrbetriqMirabegron | 21 | $8,972 |
| RestasisCyclosporine | 14 | $8,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Namzaric, Restasis, Synthroid | $989 | $223,171382 claims |
| MerckJanuvia | $25 | $38,67874 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $998 | $34,22674 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta | $226 | $22,71648 claims |
| Lilly USA, LLCTrulicity | $425 | $22,28424 claims |
| Novo NordiskRybelsus | $572 | $12,66313 claims |
| Johnson & JohnsonXarelto | $983 | $12,20119 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $174 | $8,79218 claims |
| NovartisEntresto | $11 | $7,54711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 217 geriatric medicine providers in Pennsylvania.
Other geriatric medicine in Philadelphia
- Richard StefanacciPhiladelphia$146K
- Michele ZaworaPhiladelphia$21K
- Jason KarlawishPhiladelphia$11K
- Katherine GalluzziPhiladelphia$7K
- Vladimir ZagrebelskyPhiladelphia$6K
- Lesley CarsonPhiladelphia$3K
- Helen VolokhonskyPhiladelphia$3K
- Jerry JohnsonPhiladelphia$2K
- Nicol JosephPhiladelphia$528
- James LinErie$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.